Talking Points

  • Autor: Vários
  • Narrador: Vários
  • Editora: Podcast
  • Duração: 28:57:44
  • Mais informações

Informações:

Sinopse

A selection of the best interviews conducted by physician leaders and recorded at cardiology conferences around the globe.

Episódios

  • The ILUMIEN IV Trial

    02/10/2024 Duração: 11min

    Ziad Ali and C. Michael Gibson take a deeper dive into this comparison of OCT- and angiography-guided PCI.

  • OCT vs IVUS vs Angiography: A Meta-analysis

    11/09/2024 Duração: 08min

    Gregg Stone and C. Michael Gibson discuss an updated meta-analysis addressing intravascular imaging in DES implantation.

  • The ATTRibute-CM Trial

    04/09/2024 Duração: 06min

    Julian Gillmore and C. Michael Gibson discuss the efficacy of acoramidis for patients with transthyretin amyloid cardiomyopathy.

  • The ADVENT Trial

    14/08/2024 Duração: 10min

    Vivek Reddy and C. Michael Gibson compare pulsed field ablation versus thermal ablation for patients with paroxysmal atrial fibrillation.

  • The ARAMIS Trial

    07/08/2024 Duração: 07min

    Mathieu Kerneis and C. Michael Gibson compare outcomes of patients treated with anakinra, a new therapy for acute myocarditis, or placebo.

  • The NITRATE-CIN Trial

    31/07/2024 Duração: 09min

    Dan Jones and C. Michael Gibson discuss whether inorganic nitrate reduces contrast-induced nephropathy after angiography in ACS patients.

  • The DICTATE-AHF Trial

    10/07/2024 Duração: 09min

    Zachary Cox and C. Michael Gibson discuss whether early dapagliflozin initiation is safe and effective for patients with acute heart failure.

  • The RIGHT Trial

    03/07/2024 Duração: 08min

    Shaoping Nie, Gilles Montalescot, and C. Michael Gibson discuss prolonged anticoagulation after primary PCI for patients with MI.

  • Four-Year Results: The EVOLUT Low Risk Trial

    12/06/2024 Duração: 05min

    Michael J. Reardon and C. Michael Gibson discuss the trial's 4-year results in low-surgical-risk patients with severe aortic stenosis randomized to self-expanding TAVI or SAVR.

  • The AGENT IDE Trial

    05/06/2024 Duração: 10min

    Robert W. Yeh and C. Michael Gibson discuss the primary outcomes of this eagerly awaited trial comparing the AGENT paclitaxel-coated balloon with conventional balloon angioplasty for in-stent restenosis.

  • The TRISCEND II Trial

    22/05/2024 Duração: 06min

    Susheel K. Kodali and C. Michael Gibson discuss transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation.

  • The VIVA Trial

    15/05/2024 Duração: 05min

    Josep Rodés-Cabau and C. Michael Gibson discuss the benefits of TAVI versus SAVR in patients with severe aortic stenosis and small aortic annuli.

  • The SELECT Trial

    01/05/2024 Duração: 12min

    A. Michael Lincoff and C. Michael Gibson discuss the cardiovascular impact of semaglutide in patients with overweight or obesity but without diabetes.

  • The MINT Trial

    17/04/2024 Duração: 10min

    Jeffrey Carson and Serge Korjian discuss restrictive versus liberal blood transfusion in patients with MI and anemia.

  • The ORBITA-2 Trial

    03/04/2024 Duração: 21min

    Christopher Rajkumar, Rasha Al-Lamee, and C. Michael Gibson discuss this randomized trial of PCI versus a placebo procedure for stable angina.

  • The ARIE-HM3 Trial

    14/03/2024 Duração: 14min

    Mandeep Mehra and C. Michael Gibson discuss whether or not aspirin is needed for patients with left ventricular assist devices in advanced heart failure.

  • The AZALEA - TIMI Trial

    11/03/2024 Duração: 13min

    Christian T. Ruff and C. Michael Gibson discuss the primary results of a randomized trial testing the efficacy of abelacimab versus rivaroxaban for stroke prevention in atrial fibrillation.

  • The heart-1 Trial of VERVE-101

    21/02/2024 Duração: 05min

    Andrew Bellinger, Sek Kathiresan, and C. Michael Gibson talk about the phase 1b trial of what investigators hope may be a one-time genetic fix for hyperlipidemia.

  • Lepodisiran Phase I Trial

    07/02/2024 Duração: 05min

    Steven Nissen and C. Michael Gibson discuss the efficacy and safety of lepodisiran, an extended duration short-interfering RNA meant to reduce lipoprotein (a).

  • CLEAR Outcomes Subanalysis

    24/01/2024 Duração: 10min

    Paul Ridker and C. Michael Gibson discuss whether residual inflammatory risk or residual cholesterol risk is a more effective predictor of CV events among patients treated with statins.

página 3 de 11